Many of the rheumatology societies in the Western
World have now celebrated their first half-century anniversary and have rightly congratulated themselves on their achievements. Achievements there certainly have been-the unravelling of the pathways of purine biochemistry with control of gouty arthritis, the applications of advances in immunology to the diagnosis and management of connective tissue diseases, the treatment of septic arthritis and prevention of recurrent attacks of rheumatic fever with antibiotic therapy, and the replacement of severely damaged joints by artificial prostheses.1 2 In addition, much basic information has been gathered on the biochemistry of connective tissues, the mechanics of joint lubrication and movement, the pharmacology of inflammation, the genetics of the HLA system, and the modes of action of antirheumatic drugs. Simultaneously and equally with these advances there has been an increase in membership of rheumatology societies world wide, associated with increasing numbers of abstracts and papers submitted to the ever burgeoning number of international meetings and journals. 
Future research in rheumatology
McKeown argued that 'there is a need for a shift in the balance of effort, from laboratory research to epidemiology, in recognition that improvement in health is likely to come in future, as in the past, from modifications of the conditions which lead to disease, rather than intervention in the mechanism of disease after it has occurred'.44 On the other hand, Braben has opined the opposite stating that 'the current tendency for national funding organisations to favour research based on extrapolations from present trends will inevitably have the effect of reducing diversity in national research programmes and possibly the rate at which breakthroughs occur'. 45 There is much to be said for both points of view, but the weakness in McKeown's argument is that it depends on a knowledge of the conditions which lead to the disease. This approach is not applicable to rheumatic disease, the aetiology of which is unknown. We therefore believe that emphasis must be placed on basic rather than applied research if any meaningful advances are to be made. Clinical research, however, is still necessary,' 19 The problems specifically applying to recruitment to academic rheumatology in North America relate to the economic advantages of procedure orientated disciplines. There is an urgent need if those disciplines, including rheumatology, are to flourish to reduce the currently inflated fees for procedural services and to redistribute the funds to nonprocedure orientated specialties.48 The time perhaps has also come to reward cognitive skills. 49 Training in Australasia and Britain has much to recommend it: the fellowship examination is taken early in the postgraduate training period, and research electives and doctoral theses are encouraged and recognised for final qualification. This is unlike the situation in North America where the postgraduate trainee is more often then not burdened with excessive clinical duties and has to sit an 'exit' examination at the end of his training to obtain his fellowship or boards. This leaves little opportunity for developing a research base.
Above all, such recruits to research must be freed from the stifling effect of traditional funding, which places innovativeness at a disadvantage. Peer review has been aptly described as 'the informed prejudices of wise men', and tends to cause a regression towards the mean, especially at the high end of the spectrum of significance where experiments may appear to be 'too bold'.5>53 A totally new paradigm for medical research in rheumatology is required, and for that matter for medical research in general. Medical research needs to be stimulated at all levels whether in primary care or in the molecular biological laboratory. It is essential that young persons at the start of their medical career are embued with this ethos. Research, we believe, is primarily an attitude of mind; beginning with curiosity and questioning, then planning and executing an experiment, and, finally, drawing valid conclusions. It is essential that this attitude be developed early in the undergraduate course and continued for the whole of professional life. Health care in every nation is beginning to pose an intolerable burden on the public purse. Governments must realise that if escalating health care costs are to be controlled money must be directed into basic research and into the areas of prevention and evaluation of health care technology. Control of the health care dollar will only come from a healthy association of academic medicine with all aspects of health care delivery and a stimulation of the questioning ethos across the whole spectrum of medical care providers. These considerations pertain equally to the microcosm of rheumatic diseases and to the macrocosm of medicine in general.
